KR20230142539A - 브루톤 티로신 키나제(btk) 분해제로서의 치환된 피롤로피리미딘 및 피라졸로피리미딘 - Google Patents

브루톤 티로신 키나제(btk) 분해제로서의 치환된 피롤로피리미딘 및 피라졸로피리미딘 Download PDF

Info

Publication number
KR20230142539A
KR20230142539A KR1020237029298A KR20237029298A KR20230142539A KR 20230142539 A KR20230142539 A KR 20230142539A KR 1020237029298 A KR1020237029298 A KR 1020237029298A KR 20237029298 A KR20237029298 A KR 20237029298A KR 20230142539 A KR20230142539 A KR 20230142539A
Authority
KR
South Korea
Prior art keywords
amino
piperazin
pyrimidin
dioxopiperidin
piperidin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020237029298A
Other languages
English (en)
Korean (ko)
Inventor
이민 치앤
웨이 허
로버트 루오
지에 수
후이 장
커 리우
지에 판
Original Assignee
액큐타 바이오테크놀로지 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 액큐타 바이오테크놀로지 인코포레이티드 filed Critical 액큐타 바이오테크놀로지 인코포레이티드
Publication of KR20230142539A publication Critical patent/KR20230142539A/ko
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020237029298A 2021-02-03 2022-02-02 브루톤 티로신 키나제(btk) 분해제로서의 치환된 피롤로피리미딘 및 피라졸로피리미딘 Pending KR20230142539A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163145126P 2021-02-03 2021-02-03
US63/145,126 2021-02-03
PCT/US2022/014830 WO2022169798A2 (en) 2021-02-03 2022-02-02 Substituted pyrrolopyrimidine and pyrazolopyrimidine as bruton's tyrosine kinase (btk) degraders

Publications (1)

Publication Number Publication Date
KR20230142539A true KR20230142539A (ko) 2023-10-11

Family

ID=80447078

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020237029298A Pending KR20230142539A (ko) 2021-02-03 2022-02-02 브루톤 티로신 키나제(btk) 분해제로서의 치환된 피롤로피리미딘 및 피라졸로피리미딘

Country Status (11)

Country Link
US (2) US11530222B2 (cg-RX-API-DMAC7.html)
EP (2) EP4501327A3 (cg-RX-API-DMAC7.html)
JP (1) JP2024505558A (cg-RX-API-DMAC7.html)
KR (1) KR20230142539A (cg-RX-API-DMAC7.html)
CN (1) CN117042769A (cg-RX-API-DMAC7.html)
CA (1) CA3209082A1 (cg-RX-API-DMAC7.html)
DK (1) DK4039688T3 (cg-RX-API-DMAC7.html)
ES (1) ES3010513T3 (cg-RX-API-DMAC7.html)
FI (1) FI4039688T3 (cg-RX-API-DMAC7.html)
MX (1) MX2023008865A (cg-RX-API-DMAC7.html)
WO (1) WO2022169798A2 (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202317099A (zh) * 2020-09-10 2023-05-01 美商絡速藥業公司 用於製備(s)-5-胺基-3-(4-((5-氟-2-甲氧基苯甲醯胺基)甲基)苯基)-1-(1,1,1-三氟丙烷-2-基)-1h-吡唑-4-甲醯胺之方法及中間體
EP4452945A2 (en) * 2021-12-20 2024-10-30 Sigma-Aldrich Co. LLC Chemical linkers
WO2023235691A1 (en) * 2022-05-31 2023-12-07 Accutar Biotechnology, Inc. Btk reducing molecules for treatment of cancers and immune system disorders
WO2024169871A1 (zh) * 2023-02-17 2024-08-22 江苏威凯尔医药科技有限公司 Btk抑制剂及其用途
CN120051475A (zh) * 2023-05-26 2025-05-27 广东弘烨医药科技有限公司 9元杂芳基化合物、含其的药物组合物及其制备方法和应用
KR20260041885A (ko) 2023-07-25 2026-03-27 몬테 로사 테라퓨틱스 아게 표적화된 단백질 분해를 위한 치환된 피페리딘디온
CN120535526A (zh) * 2024-02-26 2025-08-26 中国药科大学 直接结合蛋白酶体的非泛素依赖型蛋白水解靶向嵌合体NuTAC及其应用
WO2026040951A1 (zh) * 2024-08-19 2026-02-26 深圳市塔吉瑞生物医药股份有限公司 靶向btk蛋白降解靶向嵌合体类化合物及其组合物及用途

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5114946A (en) 1987-06-12 1992-05-19 American Cyanamid Company Transdermal delivery of pharmaceuticals
US4818541A (en) 1987-08-19 1989-04-04 Schering Corporation Transdermal delivery of enantiomers of phenylpropanolamine
CN105017256A (zh) * 2014-04-29 2015-11-04 浙江导明医药科技有限公司 多氟化合物作为布鲁顿酪氨酸激酶抑制剂
CN106146511A (zh) * 2015-04-03 2016-11-23 安润医药科技(苏州)有限公司 吡唑并嘧啶衍生物、制备方法、药物组合物及用途
US10611766B2 (en) * 2015-09-16 2020-04-07 Loxo Oncology Inc. Pyrazolopyrimidine derivatives as BTK inhibitors for the treatment of cancer
EP3481831B1 (en) * 2016-07-07 2023-09-06 Daewoong Pharmaceutical Co., Ltd. 4-aminopyrazolo[3,4-d]pyrimidinylazabicyclo derivatives and pharmaceutical composition comprising the same
AU2017315343A1 (en) * 2016-08-24 2019-02-28 Arqule, Inc. Amino-pyrrolopyrimidinone compounds and methods of use thereof
WO2019177902A1 (en) * 2018-03-10 2019-09-19 Yale University Modulators of btk proteolysis and methods of use
US20200038513A1 (en) * 2018-07-26 2020-02-06 Arvinas Operations, Inc. Modulators of fak proteolysis and associated methods of use
CN118027041A (zh) * 2019-05-31 2024-05-14 西藏海思科制药有限公司 一种btk抑制剂环衍生物及其制备方法和药学上的应用
WO2020252397A1 (en) * 2019-06-12 2020-12-17 Baylor College Of Medicine Small molecule proteolysis-targeting chimeras and methods of use thereof
CN112812100B (zh) * 2019-11-18 2022-04-05 四川海思科制药有限公司 一种具有降解btk激酶的化合物及其制备方法和药学上的应用
CN112979656A (zh) * 2019-12-12 2021-06-18 上海美志医药科技有限公司 一类靶向降解btk蛋白的化合物

Also Published As

Publication number Publication date
EP4039688A2 (en) 2022-08-10
JP2024505558A (ja) 2024-02-06
WO2022169798A2 (en) 2022-08-11
ES3010513T3 (en) 2025-04-03
FI4039688T3 (fi) 2024-12-19
EP4039688B1 (en) 2024-10-09
CA3209082A1 (en) 2022-08-11
EP4039688A3 (en) 2022-11-23
US20240132502A1 (en) 2024-04-25
MX2023008865A (es) 2023-08-31
EP4501327A3 (en) 2025-10-15
WO2022169798A3 (en) 2022-09-22
EP4501327A2 (en) 2025-02-05
DK4039688T3 (da) 2025-01-02
US11530222B2 (en) 2022-12-20
CN117042769A (zh) 2023-11-10
US20220259207A1 (en) 2022-08-18

Similar Documents

Publication Publication Date Title
EP4039688A2 (en) Substituted pyrrolopyrimidine and pyrazolopyrimidine as bruton's tyrosine kinase (btk) degraders
US12195459B2 (en) Glutarimide-containing pan-KRAS-mutant degrader compounds and uses thereof
US12168058B2 (en) Glutarimide-containing KRAS-mutant degrader compounds and uses thereof
AU2021218041B2 (en) Polycyclic TLR7/8 antagonists and use thereof in the treatment of immune disorders
US20240208909A1 (en) Substituted quinoline derivatives having sos1 inhibition activities and uses thereof
JP7125385B2 (ja) Tlr7/8アンタゴニストおよびそれらの使用
US20240287076A1 (en) Compounds for targeting degradation of bruton's tyrosine kinase
TW202237597A (zh) 新型egfr降解劑
TW202122382A (zh) 乙內醯脲衍生物
EP4596544A1 (en) Ep300/cbp regulator, and preparation method therefor and use thereof
AU2020413555B2 (en) PD-L1 antagonist compound
US20240132464A1 (en) Heterocyclic compounds as e3 ligase inhibitors
WO2026060424A1 (en) Akt degrader compounds and uses thereof
WO2026072966A2 (en) Pi3k degrader compounds and uses thereof

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20230829

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application